Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVRx, Inc.CVRX · Entity 6920 | Chief Medical Officer | February 27, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVRx, Inc.
Report date February 27, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,840 |
Reported balance
After 2026-02-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 41,000 · Balance 62,840 F1: Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date. F2: Includes 1,840 shares acquired under Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 61,578 |
Reported balance
After 2026-03-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-02 · Sale · Disposed 1,262 · Balance 61,578 F3: The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction. F4: Reflects the weighted average price of 1,262 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $8.00 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2036-02-26 | Direct | 62,000 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Grant · Acquired 62,000 · Balance 62,000 F5: Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date.
F2: Includes 1,840 shares acquired under Issuer's Employee Stock Purchase Plan.
F3: The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction.
F4: Reflects the weighted average price of 1,262 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $8.00 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 16, 2026 16:16 UTC | CVRx, Inc. CVRX · Entity 6920 | SaleCommon Stock | 1,262 | $7.90 | $9,973.21 |
DisclosureSEC source: 0002056191-26-000004 · form4-03162026_080309.xml · nonDerivative · entry 2 Adamson Philip B. · CIK 0002056191 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,578 F3 · kind: The sale was mandated by the issuer's award agreement to satisfy tax withholding obligations by a sell-to-cover transaction. F4 · price: Reflects the weighted average price of 1,262 shares of common stock of CVRx, Inc. sold by the reporting person in multiple transactions on March 2, 2026 with sale prices ranging from $7.90 to $8.00 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 27, 2026 Filed Mar 16, 2026 16:16 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 62,000 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0002056191-26-000004 · form4-03162026_080309.xml · derivative · entry 3 Adamson Philip B. · CIK 0002056191 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2036-02-26 F5 · derivative.exercise_date: Vests as to 25% of the shares on February 27, 2027 and as to 1/48th of the shares each month thereafter. Read SEC document |
| February 27, 2026 Filed Mar 16, 2026 16:16 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantCommon Stock | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002056191-26-000004 · form4-03162026_080309.xml · nonDerivative · entry 1 Adamson Philip B. · CIK 0002056191 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,840 F1 · shares: Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date. F2 · balance_after: Includes 1,840 shares acquired under Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:11 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001415889-25-006481 · form4-03042025_090314.xml · derivative · entry 2 Adamson Philip B. · CIK 0002056191 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-02-27 F2 · derivative.exercise_date: Vests as to 25% of the shares on February 28, 2026 and as to 1/48th of the shares each month thereafter. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:11 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006481 · form4-03042025_090314.xml · nonDerivative · entry 1 Adamson Philip B. · CIK 0002056191 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Restricted stock units that vest as to 25% of the shares on each annual anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.